News & Events
FDA Clears Magstim Transcranial Magnetic Stimulation System Horizon 3.0 with StimGuide Pro

FDA Clears Magstim Transcranial Magnetic Stimulation System Horizon 3.0 with StimGuide Pro

Magstim has been awarded FDA clearance for the Horizon 3.0 with StimGuide Pro. This provides physicians, nurse practitioners, clinicians, and researchers with the most advanced transcranial magnetic stimulation technology (TMS) available to treat patients diagnosed with depressive or obsessive-compulsive conditions.

ECT and Neuromodulation Conference London

 ECT and NEUROMODULATION CONFERENCE LONDON30 November through 1 December.Magstim is excited to announce our presence at the Annual ECT and Neuromodulation Conference, taking place at The Royal College of Psychiatrists in London from November 30th to December 1st.Meet Derin Rose…

Magstim EGI Live TMS and EEG At SFN 2023

Magstim EGI Leads Live TMS EEG Demonstrations at SFN 2023 The annual Society for Neuroscience (SFN) conference is one of the most eagerly anticipated events for neuroscientists, researchers, and professionals from around the world. This year, SFN is set to…

FDA clears Magstim transcranial magnetic stimulation for obsessive compulsive disorder

Non-invasive Treatment Cleared for Treating Patients Diagnosed with OCD MINNEAPOLIS, Minn. – (January 18, 2023) – Magstim, a global leader in neuroscience research and Transcranial Magnetic Stimulation (TMS) solutions for mental health, announced today that the FDA has cleared the Horizon 3.0 (with…
Magstim Insights Ready to Read Now

Magstim Insights Ready to Read Now

Have you seen the latest issue of Magstim Insights?Click to read our inspiration edition.
NEW MAGSTIM ANALYTICS SOFTWARE OFFERS POWERFUL TMS DATA FOR PRACTICES, TREATERS AND DEVICE REPORTING

NEW MAGSTIM ANALYTICS SOFTWARE OFFERS POWERFUL TMS DATA FOR PRACTICES, TREATERS AND DEVICE REPORTING

HIPAA Compliant TMS software provides new level of data designed to improve quality control metrics for patients and practices MINNEAPOLIS, Minn. & Carmarthenshire, UK – (April 28, 2022) – Magstim, the global leader in neuroscience research and treatment for mental…

Welcony Inc Appoints Ronnie Stolec-Campo To Lead Global Business

Welcony Inc, a global neurotechnology leader, announces that Ronnie Stolec-Campo will now lead the business. As CEO, she succeeds Lothar Krinke, PhD, who announced his departure from the organization. Stolec-Campo will not continue her role as Chief Financial Officer for…

Magstim Horizon 3.0 First Impressions Video

Listen to what these top TMS clinical professionals had to say about the new Magstim H3.0 Thanks to John Cavanagh and Carla Weatherford, Restore-Brain and to Lilly Sanchez, Genesis Behavioral Health. https://www.youtube.com/watch?v=nXfv4TlQYLY
GROUNDBREAKING STUDY: After TMS treatment, 65.3% of Veterans with co-morbid PTSD and MDD demonstrated clinically meaningful reduction

GROUNDBREAKING STUDY: After TMS treatment, 65.3% of Veterans with co-morbid PTSD and MDD demonstrated clinically meaningful reduction

In the largest study of its kind to date, medical researchers with the U.S. Department of Veterans Affairs (VA) supports the effectiveness and safety of transcranial magnetic stimulation for veterans with MDD and PTSD using standard clinical approaches. As published in…

Keep up to date

By signing up you are confirming that you have read, understood and accept our Privacy Policy